LAUSR

Approximately a quarter of the world population had been infected with Mycobacterium tuberculosis, and about 5 to 10% of these individuals might develop active disease in their lifetimes. As a critical component of the “end TB strategies,” preventive treatment was shown to protect 60 to 90% of high-risk LTBIs from developing active disease. ABSTRACT Individuals with latent tuberculosis infection (LTBI) were regarded as an enormous reservoir of cases with active tuberculosis (TB). To strengthen LTBI management, biomarkers and tools are urgently required for identifying and ruling out active TB in a fast and effective way. Based on an open-label randomized controlled trial aiming to explore short-course LTBI treatment regimens, DNA methylation profiles were retrospectively detected to explore potential biomarkers, which could discriminate active TB from LTBI. The Infinium MethylationEPIC BeadChip array was used to analyze genomewide DNA methylation levels for 15 persons with LTBI who later developed active TB and for 15 LTBI controls who stayed healthy. The differentially methylated CpGs (dmCpGs) located in the promoter regions pre- and post-TB diagnosis were selected (P < 0.05 and |Δβ|>0.10) and evaluated by receiver operating characteristic (ROC) analysis. Eight dmCpGs were identified to be associated with TB occurrence; six were located in hypermethylated genes (cg02493602, cg02206980, cg02214623, cg12159502, cg14593639, and cg25764570), and two were located in hypomethylated genes (cg02781074 and cg12321798). ROC analysis indicated that the area under curve (AUC) of these eight dmCpGs ranged from 0.72 to 0.84. Given 90% sensitivity, the specificity was highest for cg14593639 at 66.67%. The combination analysis indicated that “cg02206980 + cg02214623 + cg12159502 + cg12321798” showed the best performance, with an AUC of 0.88 (95% confidence interval [CI]: 0.72, 0.97), a sensitivity of 93.33% (95% CI: 70.18%, 99.66%), and a specificity of 86.67% (95% CI: 62.12%, 97.63%). Our preliminary results indicate the potential value of the DNA methylation level as a diagnostic biomarker for discriminating active disease in LTBI testing. This finding requires further verification in independent populations with large sample sizes. IMPORTANCE Approximately a quarter of the world population had been infected with Mycobacterium tuberculosis, and about 5 to 10% of these individuals might develop active disease in their lifetimes. As a critical component of the “end TB strategies,” preventive treatment was shown to protect 60 to 90% of high-risk LTBIs from developing active disease. Developing new TB screening tools based on blood-based biomarkers, which could identify and rule out active TB from LTBI, are prerequisite before initialing intervention. We tried to explore potential DNA methylation diagnostic biomarkers through retrospectively detected DNA methylation profiles pre- and post-TB diagnosis. Eight dmCpGs were identified, and the combination of “cg02206980 + cg02214623 + cg12159502 + cg12321798” showed a sensitivity of 93.33% and a specificity of 86.67%. The preliminary results provided new insight into detecting the DNA methylation level as a potential tool to distinguish TB from LTBI.